ZEISS Vision Care is bolstering its myopia management portfolio with the acquisition of Brighten Optix, a leading player in orthokeratology (orthok) and specialty contact lenses.
Announced on 4 June 2025, Carl Zeiss Vision International GmbH has entered a definitive agreement to acquire 100% of the shares in the company, listed on Taipei Exchange.
“The capability and products of Brighten Optix will now play an important role in ZEISS Vision Care’s long-term strategy and success,” ZEISS said.
“With this acquisition, ZEISS Vision Care is making a strong addition to its already successful myopia management portfolio.”
Brighten Optix products – including some of the market’s most advanced brands such as myOK – are widely available and used by eyecare professionals and eye clinics in Greater China and across Southeast Asia.
“Progressive myopia is one of the biggest vision care challenges we see in the world today,” said Mr Sven Hermann, CEO of ZEISS Vision Care and member of the executive board of ZEISS.
“The topic is so important as the sight of children is at risk. We are already proud of our spectacle lens portfolio, which is clinically proven to significantly slow the progression of myopia. But at the same time, we also know that we need to offer even more options to our partners, the doctors and eyecare professionals.
“That is why we are delighted to have found such a great partner. Our future partnership will allow us to meet exactly this need. We will broaden our portfolio and enable our customers to protect and improve the vision of many more children.”
Mr Richard Wu, general manager of Brighten Optix, said he was excited to join a company like ZEISS.
“Our business has flourished thanks to pioneering, industry-leading products, and we’re eager to capitalise on this chance to help grow and shape the future of vision care and in particular contact lenses and myopia management,” he said.
“Personally, I am proud and thankful to everyone at Brighten Optix for their unwavering commitment and expertise in improving and protecting vision over the last 50 years since my father founded the company. And I am confident that the talented teams of Brighten Optix and ZEISS Vision Care will accomplish great things together.”
The acquisition is expected to close early 2026. The transaction remains subject to completion of certain conditions and all applicable regulatory approvals.
More reading
Optipro forms “strategic partnership” with ZEISS in Australia
Latest data confirms ZEISS MyoCare slows myopia progression
ZEISS delivering the premium, golden touch in lenses
